Clinical trialUNITERAREMay 8
New Recruiting Trial: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Researchers are testing a new vaccine called CMV-MVA Triplex Vaccine to help patients who are receiving a special type of bone marrow transplant called haploidentical stem cell transplant. Cytomegalovirus (CMV) is a common virus that can cause serious problems after this type of transplant. This vaccine is designed to strengthen the body's immune system against CMV and prevent the virus from spreading in the blood.
WHY IT MATTERSThis trial is now recruiting patients undergoing haploidentical hematopoietic stem cell transplant at City of Hope Medical Center — CMV reactivation is a major cause of complications and death after this procedure, making this preventive vaccine potentially life-changing for transplant recipients.